XASXFRE
Market cap8mUSD
Jan 02, Last price
0.06AUD
1D
-1.59%
1Q
5.08%
IPO
-69.00%
Name
Firebrick Pharma Ltd
Chart & Performance
P/E
—
P/S
897.03
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
1.18%
Rev. gr., 5y
%
Revenues
15k
+1,649.64%
Net income
-1m
L-82.71%
CFO
-2m
L-59.45%
Profile
Firebrick Pharma Limited engages in the development and commercialization of nasal spray treatment for the common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | |
| Income | ||||||
Revenues | 15 1,649.64% | 830 -79.87% | 4 -99.02% | |||
Cost of revenue | 2,416 | 4,751 | 3,047 | |||
Unusual Expense (Income) | ||||||
NOPBT | (2,402) | (4,750) | (3,043) | |||
NOPBT Margin | ||||||
Operating Taxes | (22) | 1,083 | ||||
Tax Rate | ||||||
NOPAT | (2,402) | (4,728) | (4,126) | |||
Net income | (1,176) -82.71% | (6,802) 79.18% | (3,796) 55.65% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 815 | 990 | 10,226 | |||
BB yield | -8.13% | -3.76% | ||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (825) | (2,355) | (7,143) | |||
| Cash flow | ||||||
Cash from operating activities | (2,345) | (5,783) | (4,202) | |||
CAPEX | (134) | (2) | (33) | |||
Cash from investing activities | (134) | (2) | (33) | |||
Cash from financing activities | 815 | 997 | 10,226 | |||
FCF | (3,371) | (3,985) | (4,585) | |||
| Balance | ||||||
Cash | 825 | 2,355 | 7,143 | |||
Long term investments | ||||||
Excess cash | 824 | 2,355 | 7,143 | |||
Stockholders' equity | 2,115 | 2,476 | 8,279 | |||
Invested Capital | 1,291 | 121 | 1,137 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 179,016 | 170,092 | 168,844 | |||
Price | 0.06 -63.87% | 0.16 | ||||
Market cap | 10,025 -61.98% | 26,364 | ||||
EV | 9,200 | 24,010 | ||||
EBITDA | (2,395) | (4,740) | (3,036) | |||
EV/EBITDA | ||||||
Interest | 1 | 4 | ||||
Interest/NOPBT | ||||||